FIELD: organic chemistry, medicine, endocrinology. SUBSTANCE: invention relates to a novel therapeutic drug used for treatment of patients with diabetes mellitus that involves the compound of the formula (I): 
where X means the group of the formula: -C(R4)(R5)-,-N(R6)-, - O- where R4 means hydrogen atom, C1-C5-alkyl, carboxy-group, phenyl, C2-C5-acyl, C2-C5-alkoxycarbonyl; R5 means hydrogen atom, C1-C5-alkyl; R6 means hydrogen atom; R1 means phenyl optionally substituted with C1-C5-alkyl, hydroxy-group, hydroxyalkyl, C2-C6-alkenyl, acyl, carboxy-group, thienyl-group, C3-C7-cycloalkyl; biphenyl optionally substituted with C1-C5-alkyl or hydroxy-group; naphthyl; terphenyl; C3-C7-cycloalkyl optionally substituted with C1-C5- alkyl or phenyl; optionally substituted C1-C5-alkyl; pyridyl; benzothienyl; adamantyl; indanyl; fluorenyl or the group 
; R2 is hydrogen atom, C1-C5- -alkyl optionally substituted with carboxy-group; 
is hydrogen atom; R3 is C1-C5- alkyl optionally substituted with phenyl or C1-C4-alkoxy-group; C1-C4-alkoxy-group; hydroxy-group; phenyl; C3-C7- cycloalkyl optionally substituted with C1-C5-alkyl; R2 and R7 taken in common form the group -(CH2)2-; R2 and R5 taken in common form a simple bond or -CH2-, -(CH2)3-, -(CH2)4-; 
taken in common form = CH-CH= CH-CH= ; 
and R3 taken in common form -CH(R8)-O, -CH(R8)-CH(R9)-, -CH(R8)NH; R8 and R9 means hydrogen atom its pharmaceutically acceptable salts. Invention describes also compounds of the formula (II) (is given the specification) where 
means hydrogen atom; 
is C3-C7-cycloalkyl mono- -substituted with C1-C4-alkyl, phenyl; if 
means C1-C4-alkoxy- -group then 
means C2-C5-acyl, C2-C5-alkoxycarbonyl; 
is C3-C7- - cycloalkyl monosubstituted with C1-C4-alkyl, phenyl or its pharmaceutically acceptable salts. Compounds of the formula (III) 
where if 
is hydroxy-group then 
is hydrogen atom, C1-C4-alkyl, carboxy-group; 
means hydrogen atom or C1-C4- -alkyl; R101 means C1-C4-alkyl substituted with hydroxy-group; if 
is C1-C4-alkyl then 
is hydrogen atom, C2-C5-acyl; 
is hydrogen atom, C1-C4-alkyl; R101 is C1-C4/ -alkyl substituted with hydroxy-group or phenyl substituted with carboxy-group, hydroxy- -group or phenyl, its pharmaceutically acceptable salt, hydrate or solvate. Compounds of the formula (IV) 
where A and B are different and mean CH2, NH, O and if 
is hydrogen atom then 
is C1-C4-alkyl substituted with hydroxy-group or phenyl; or if 
is C1-C4-alkyl, then 
-hydrogen atom, C1-C4-alkyl substituted with hydroxy-group or phenyl; its pharmaceutically acceptable salt, hydrate or solvate. Compounds do not show adverse effects and decrease blood glucose level in hyperglucaemic patients. EFFECT: new agent indicated above, valuable antidiabetic properties of drug. 32 cl, 4 dwg, 31 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF PROPIONIC ACID AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1997 |
|
RU2174121C2 |
| METHOD OF SYNTHESIS OF OXAZOLE COMPOUND | 1999 |
|
RU2194042C1 |
| METHOD OF SYNTHESIS OF ISOXAZOLIDINEDIONE COMPOUND, METHOD OF SYNTHESIS OF OXAZOLYLETHANOL COMPOUND (VARIANTS), METHOD OF SYNTHESIS OF ASPARTATE COMPOUND, METHOD OF SYNTHESIS OF OXAZOLYLACETATE COMPOUND, METHOD OF SYNTHESIS OF METHANESULFONATE COMPOUND, METHOD OF SYNTHESIS OF BENZYLIDENE COMPOUND | 1999 |
|
RU2180663C2 |
| INHIBITOR OF ACTIVITY OF CHOLESTEROL ESTERIFIED TRANSPORT PROTEIN, PROPHYLACTIC OR THERAPEUTIC AGENT, DERIVATIVES OF BIS-(2-AMIDOPHENYL)-DISULFIDE OR AMIDOTHIOPHENOL | 1998 |
|
RU2188631C2 |
| NITROGEN-CONTAINING SPIROCYCLIC COMPOUND AND ITS APPLICATION IN MEDICINE | 2010 |
|
RU2630694C2 |
| HETEROCYCLIC COMPOUNDS | 2006 |
|
RU2383539C2 |
| 4-OXOQUINOLINE COMPOUND AND ITS USING AS HIV INTEGRASE INHIBITOR | 2003 |
|
RU2275361C2 |
| ESTER DERIVATIVES AND THEIR MEDICAL APPLICATION | 2005 |
|
RU2431480C2 |
| PYRAZOLE COMPOUND AND ITS PHARMACEUTICAL USE | 2012 |
|
RU2617678C2 |
| TRIAZOLOPYRIDINE COMPOUND AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | 2010 |
|
RU2538963C2 |
